Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studiesRichard S Finn, Kangsheng Gu, Xi Chen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 8, 2024
Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohortAntoine Lebeaud, Leony Antoun, Jane-Rose Paccard, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.
The Lancet Regional Health. Europe|March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across EuropeLorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
Pageof 16